SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of patients with inoperable liver tumours.


SIR-Spheres Y-90 resin microspheres are contraindicated in patients who have:

  • had previous external beam radiation therapy to the liver;
  • ascites or are in clinical liver failure;
  • markedly abnormal synthetic and excretory liver function tests (LFTs);
  • greater than 20% lung shunting of the hepatic artery blood flow determined by Technetium-99m macroaggregated human albumin (99mTc-MAA)  scan;
  • pre-assessment angiogram that demonstrates abnormal vascular anatomy that would result in significant reflux of hepatic arterial blood to the stomach, pancreas or bowel;
  • disseminated extra-hepatic malignant disease;
  • been treated with capecitabine within the two previous months, or who will be treated with capecitabine at any time following treatment with SIR-Spheres Y-90 resin microspheres.
  • portal vein thrombosis.


  • Inadvertent delivery of SIR-Spheres Y-90 resin microspheres to the gastrointestinal tract or pancreas will cause acute abdominal pain, acute pancreatitis or peptic ulceration. 
  • High levels of implanted radiation and/or excessive shunting to the lung may lead to radiation pneumonitis.
  • Excessive radiation to the normal liver parenchyma may result in radiation hepatitis.
  • Inadvertent delivery of SIR-Spheres Y-90 resin microspheres to the gallbladder may result in cholecystitis.


  • Safety and effectiveness of this device in pregnant women, nursing mothers or children have not been established.
  • A SPECT scan of the upper abdomen may be performed immediately after implantation of SIR-Spheres Y-90 resin microspheres. The SPECT scan will detect the Bremsstrahlung radiation from the yttrium-90 to confirm placement of the microspheres in the liver.
  • This product is radioactive. Local regulations must be followed when handling this device.
  • Some patients may develop gastritis following treatment. Gastric acid blocking drugs may be used the day before implantation of SIR-Spheres Y-90 resin microspheres and continued as needed to reduce gastric complications.
  • Many patients may experience abdominal pain immediately after administration of SIR-Spheres Y-90 resin microspheres and pain relief may be required.
  • SIR-Spheres Y-90 resin microspheres demonstrated a mild sensitisation potential when tested dermally in an animal model.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage